Jefferies analyst Akash Tewari maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) on February 3 and set a price target of ...

Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of ...

Industry giants like Takeda Pharmaceuticals, Pfizer, Novartis, and Bayer are revolutionizing treatment landscapes, paving the way for enhanced patien ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce ...

Leading the elite Wall Street firm Cravath, he became a go-to adviser on mergers and acquisitions — “all the big deals that ...

Bristol Myers Squibb Co. closed 3.24% short of its 52-week high of $61.10, which the company reached on January 27th.

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...